Global Cancer Biomarkers Market: Snapshot
Cancer is a complex and potentially fatal disease that is primarily caused through environmental factors resulting in gene mutations affecting critical cell-regulatory proteins. These factors may act together or in a sequence to trigger tumor formation. Rising incidences of cancer and increasing healthcare expenditure are expected to aid the global cancer biomarkers market. The global market for cancer biomarkers is expected to grow at an exponential rate benefiting from the recent advances in technology, favorable government initiatives and funding.
Moreover, the development in companion diagnostics and recent breakthrough in detection techniques such as proteomics, metabolomics, genomics and transcriptomics are further expected to boost the demand for cancer biomarkers. Cancer biomarker is critical in improving early detection and treatment of any cancer type. Awareness and screening for cancer have increased over the last couple of decades resulting in early diagnosis of cancer and subsequent reduction of mortality. However, the ultimate goal of reducing mortality in late-stage cancer has not been satisfactorily achieved.
Besides this, the cancer biomarkers market is expected to gain from the rising geriatric population, increasing incidences of cancer, and increasing prevalence of tumor. Technological advancements in the field of biomarkers resulting in new and innovative products have increased the safety, improved efficacy and reduced the side effects. Spurred by these factors, the global cancer biomarkers market is forecast to exhibit a CAGR of 11.8% between 2017 and 2025. At this pace, the market is expected to reach US$27.63 bn by the end of 2025 from US$10.25 bn in 2016.
Lung Cancer Emerges as Leading Segment Based on Disease Indication
The CTC tests segment by test type accounted the largest share of the global cancer biomarkers market in 2016, and is expected to dominate the market during the forecast period from 2017 to 2025. Factors such as increase in prevalence of the various types of tumor and increasing incidences of cancer related to the vital organs drives the CTC tests segment. Although associated with non-drivers of selection, such as quick and easy order processing and availability from a contracted manufacturer, the cancer biomarkers market presents immense competition for new market players.
The lung cancer segment in terms of disease indication has the largest market share of the global cancer biomarkers market in 2016, and is expected to grow during the forecast period due to increasing prevalence of lung cancer in developing countries, growing cigarette smoking among the population, rising geriatric population, and technological advancements with regard to lesser side effects associated with biomarkers test and early detection of the illness drive demand for lung cancer diagnosis globally.
North America to Remain Dominant Regional Market through Forecast Period
North America dominated the global cancer biomarkers market in 2016 and is expected to remain dominant through the forecast period. This is due to high prevalence of cancer, increasing health care expenditure leading to increase in demand for better diagnostic tests and health care services, and number of technological advancements in the field of cancer biomarkers. However, the market in Asia Pacific is projected to register a significant growth rate by 2025 due to availability of large patient pool and increasing awareness about health. In addition, high percentage of geriatric population, and increasing disposable income are expected to propel the market.
Major players operating in the global cancer biomarkers market include Abbott Laboratories, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Illumina, Inc., Agilent Technologies, QIAGEN, Merck & Co., Inc., Hologic, Inc., Novartis AG, bioMérieux SA, Genomic Health, Inc., are among others.
Global Cancer Biomarkers Market: Overview
Biomarkers are the substance or molecules found in blood, other body fluids or tissues which states the normal and abnormal condition of the body, biomarkers helps to detect various diseases such as cancer. Cancer biomarkers tests are carried out to detect genes or mutated genes responsible for cancer. Dramatic improvement in the cancer biomarkers tests will increase demand globally.
A detailed overview of market dynamics, including the drivers, restraints, and opportunities of the cancer biomarkers market, has been provided in this report. Market revenue for all the above mentioned segments, and their sub segments has been provided for the forecast period of 2017-2025, considering 2016 as the base year, and 2015 as the historical year, along with compound annual growth rate (CAGR %), for the forecast period of 2017-2025. Market share estimations were based on in-depth analysis and study of products, and their features, prices etc.
This report provides in-depth analysis of the cancer biomarkers market. The stakeholders for this report include companies involved in the reagent manufacturer for cancer biomarkers tests. For providing a snapshot of this market to the stakeholders, executive summary section is included in this report, which summarizes the market size, trends and competition in different regions. Market share analysis among the market players is analyzed to signify percentage share of the major players operating in the cancer biomarkers market. Furthermore, the report incorporates market attractiveness analysis by geography that depicts the most attractive and significant region in the global market in 2015.
The research methodology is a combination of primary and secondary research. Primary research includes information collected via e-mails, and telephonic interviews of Key Opinion Leaders (KOL), and forms the bulk of our research. Secondary research includes information collected from various sources, by study of company websites, annual reports, stock analysis presentations, press releases, and various national and international databases.
Global Cancer Biomarkers Market: Segmentation
Based on test type, global cancer biomarkers market are segmented into PSA tests, CTC tests, AFP tests, CA tests, HER2 tests, BRCA tests, ALK tests, CEA tests, EGFR Mutation tests, KRAS Mutation tests and others. Based on disease indication, the cancer biomarkers market are segmented into breast cancer, lung cancer, colorectal cancer, melanoma, blood cancer, prostate cancer, ovarian cancer, stomach cancer, liver cancer and others.
Based on geography, the cancer biomarkers market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The regions are further segmented into major countries which include, U.S., Canada, Germany, U.K., France, Spain, Italy, Russia, rest of Europe, India, China, Japan, Australia and New Zealand, Rest of Asia Pacific, Brazil, Mexico, Rest of Latin America, GCC countries, South Africa and Rest of Middle East and Africa.
Companies Mentioned in the Report
The report also comprises list major players in the market, their SWOT analysis, market share of these players in the cancer biomarkers, key business strategies, product portfolios, and recent developments. Key market players profiled in this report include, Abbott Laboratories, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Illumina, Inc., Agilent Technologies, QIAGEN, Merck & Co., Inc., Hologic, Inc., Novartis AG, bioMérieux SA, Genomic Health, Inc. and others
The global cancer biomarkers market has been segmented as follows:
- Global Cancer Biomarkers Market, by Test Type
- PSA Tests
- CTC Tests
- AFP Tests
- CA Tests
- HER2 Tests
- BRCA Tests
- ALK Tests
- CEA Tests
- EGFR Mutation Tests
- KRAS Mutation Tests
- Global Cancer Biomarkers Market, by Disease Indication
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Blood Cancer
- Prostate Cancer
- Ovarian Cancer
- Stomach Cancer
- Liver Cancer
- Global Cancer Biomarkers Market, by Geography
- North America
- Rest of Europe
- Asia Pacific
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- GCC countries
- South Africa
- Rest of MEA
- North America